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Abstract
In learn-as-you-go (LAGO) adaptive studies, the intervention is a complex package
consisting of multiple components, and is adapted in stages during the study based
on past outcome data. This design formalizes standard practice, and desires for
practice, in public health intervention studies. An effective intervention package is
sought, while minimizing intervention package cost. When analyzing data from a
learn-as-you-go study, the interventions in later stages depend upon the outcomes
in the previous stages, violating standard statistical theory. We develop methods
for estimating the intervention effects in a LAGO study. We prove consistency and
asymptotic normality using a novel coupling argument, ensuring the validity of the
test for the hypothesis of no overall intervention effect. We develop a confidence set
for the optimal intervention package and confidence bands for the success probabilities
under alternative package compositions. We illustrate our methods in the BetterBirth
Study, which aimed to improve maternal and neonatal outcomes among 157,689 births
in Uttar Pradesh, India through a complex, multi-component intervention package.
Keywords: Adaptive Designs; Dependent Sample; Coupling; Public Health; Implementa-
tion Science
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1 Introduction
Adaptive designs have been developed and have been available for use in clinical trials for
decades. The U.S. Food and Drug Administration defines an adaptive design as “...a clinical
study design that allows for prospectively planned modifications based on accumulating
study data without undermining the study’s integrity and validity” (FDA, 2016).
The existing literature on adaptive designs has thus far considered several types of
prospectively planned design modifications, including blinded sample size reassessment,
group sequential testing, interim analysis for benefit or futility, successive re-randomization,
changing subgroup proportions or eligibility criteria of the trial (Rosenblum and van der Laan,
2011) and dropping treatment arms. Prominent among the techniques developed to pre-
serve the validity of statistical inference when design adaption has occurred is the condi-
tional error function (Proschan and Hunsberger, 1995; Mu¨ller and Scha¨fer, 2001, 2004),
and combination functions have been used to aggregate p-values from multiple stages
(Bauer and Kohne, 1994; Brannath et al., 2002). See Kairalla et al. (2012); Bauer et al.
(2016) for recent comprehensive reviews of adaptive designs in clinical trials. In addi-
tion to valid testing, methods have been developed for estimation in an adaptive group
sequential design (e.g. Gao et al., 2013).
The present work is motivated by large-scale public health intervention studies of com-
plex multi-component intervention packages. In the newly proposed “learn-as-you-go”
(LAGO) design, the intervention, which can e.g. be a treatment, a device, a new way
to organize care, or, more likely, a combination thereof, is composed of several components.
While subject matter experts have some knowledge with regard to the preferred interven-
tion package, in LAGO, optimal development of the intervention package is an inherent
part of the study goals. A LAGO study is conducted in stages. After each stage, the
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data collected so far are analyzed, the intervention package is reassessed, and a revised
intervention package is rolled out in the next stage. Unlike previous adaptive designs, in
the LAGO design, the composition of the intervention package in later stages depends on
the outcomes from previous stages.
The Sequential Multiple Assignment Randomized Trial (SMART) design (Murphy,
2005; Murphy et al., 2007) randomizes study participants at more than one time point
to pre-specified randomization options with probabilities that depend on participant’s past
characteristics and outcomes. The aim of a SMART trial is to estimate the optimal se-
quence of treatments given patient’s covariate and response histories up to the present. It is
a non-adaptive design method which optimizes a personalized and dynamic intervention, in
part by restricting randomization options at each step. In contrast, LAGO identifies a com-
plex static, possibly ‘cluster-personalized’, intervention package where, unlike in SMART,
the options are unknown at the start of the trial and are estimated anew as a result of
trial data up to the current stage. In addition, LAGO studies will add new centers, with
new participants, entering at each stage, while in SMART the same individuals are repeat-
edly re-randomized. Both design strategies are well suited for complex multi-component
interventions.
The multiphase optimization strategy (MOST, Collins et al., 2007, 2014) consists of
three phases: preparation, optimization and evaluation. The optimal intervention package
is developed during the optimization phase, followed by its formal statistical evaluation in a
randomized controlled trial. The aim of MOST is similar to LAGO: to develop an optimal
intervention package and estimate its impact. However, in MOST, the outcomes of the
past are used at most in one stage, to determine the optimal package in the optimization
phase. The resulting package is then independently studied through a controlled trial in
the evaluation phase, using no prior data.
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At face value, phase I dose-finding studies have perhaps the greatest similarity to the
LAGO design paradigm. In dose-finding studies, the goal is to find the maximum tolerated
dose, that is, the highest dose of a drug such that adverse effects of the drug are below a
pre-determined threshold. Dose values are assigned to patients in a sequential manner, and
in each step a decision is made to stop and declare that the maximum tolerated dose has
been found, or to continue, and if so, with which dose. The more traditionally used methods
include the “3 + 3” and “accelerated titration” designs (Simon et al., 1997; Wong et al.,
2016). Another popular method is the continual reassessment method (O’Quigley et al.,
1990; O’Quigley and Shen, 1996), which assigns each patient the current estimated maxi-
mum tolerated dose. Methods were also developed for the optimal dose of two drugs simul-
taneously (Thall et al., 2003; Wang and Ivanova, 2005). Rosenberger and Haines (2002)
provide a review of the continual reassessment method and additional statistical methods
for dose finding studies. Dose-finding studies are generally too small for the application
of asymptotic statistical methods, and typically Bayesian approaches have been used. In
contrast, in public health intervention studies, the magnitude of the per-stage sample size
is typically much larger than the sample size in dose-finding studies, while the maximum
number of stages will be limited. Additionally, unlike dose-finding studies, where methods
are considered for a single or at most dual treatments, the complex public health interven-
tions motivating the development of the LAGO design feature multiple components, some
of which are continuous, while others are binary (Hallberg and Richards, 2015).
An ad hoc example of a precursor to a formal LAGO study is the “BetterBirth Study”
(Hirschhorn et al., 2015; Semrau et al., 2017) of Ariadne Labs, led by Atul Gawande (Gawande,
2014), a joint center of the Brigham and Women’s Hospital and the Harvard T.H. Chan
School of Public Health. The BetterBirth Study assessed the use of the World Health
Organization’s (WHO) Safe ChildBirth checklist, a 31-item checklist of best labor and de-
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livery practices believed to be feasible in resource-limited settings, to reduce maternal and
neonatal mortality. The intervention was adapted and tested in a three phase process in
Uttar Pradesh, India, where neonatal mortality is 32 per 1000 live births and maternal
mortality is 258 per 100,000 births (Semrau et al., 2017). During the first two phases, the
intervention was adapted, and a final version was tested in a cluster randomized trial. This
work was generously funded through a grant from the Bill & Melinda Gates Foundation,
and included 157,689 mothers and newborns.
The first goal of a LAGO study is to identify the optimal intervention package such that
the cost of the intervention is minimized and the probability of a desired binary outcome
is above a given threshold. For example, in the BetterBirth Study, the outcome could be
the use of the WHO Safe ChildBirth checklist, with the aim being, for example, that the
checklist is used during at least 90% of the births. In the illustrative example included in
this paper, we investigate a process outcome, oxytocin administration after delivery, with
the aim being that 85% of mothers will receive oxytocin after delivery, as recommended by
the WHO, as a proven intervention for preventing postpartum hemorrhage. We determine
whether the use of a multiple component intervention package that includes on-site coaching
visits and an intervention launch of a particular duration, increases the administration of
oxytocin, compared to standard of care.
The second goal of a LAGO study is to assess the overall impact of the intervention
strategy, as well as that of its individual components. We present methodology to achieve
both goals.
In a LAGO study, the data are not an independent sample. Beginning with the second
stage, the recommended intervention package is itself a random variable that depends on
previous outcomes. In the final analysis, a LAGO study uses the data from all stages.
When considering the asymptotic behavior of the estimators, we assume that the sample
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size in each stage increases at a similar rate. In addition, we assume that the intervention
in each stage converges in probability to a constant as the number of observations in the
previous stage goes to infinity. This would happen, under the usual regularity conditions,
if the intervention in each stage is based on a maximum likelihood estimator obtained from
the data collected in previous stages.
LAGO studies can be further characterized by a key design feature which determines
the strength of the causal inferences that can be made. In an uncontrolled LAGO study,
there are neither baseline data available to permit a quasi-experimented before-after com-
parison nor randomized or non-randomized planned variation in the implementation of the
intervention package. Thus, unplanned variation, which is widespread in large-scale pub-
lic health interventions, serves as the basis for making causal contrasts. Causal inference
methods will thus be needed to adjust for possible confounding bias (Hernan and Robins,
2019; Spiegelman and Zhou, 2018). In a controlled LAGO study, baseline outcome data
are collected before the intervention is implemented, or in additional centers in which no
intervention was implemented. These additional centers may be randomized or not, to be
included in the study as controls. In the design where baseline data serves as the con-
trol, the quasi-experimental before-after design serves as the basis for causal contrasts. If,
instead or in addition, there are concurrent control centers, stronger causal inference is
permitted by design, with the strongest design being a randomized controlled before-after
set-up.
We propose estimators for a LAGO study allowing for several stages, multiple centers
or sites, multiple component complex interventions, and center-specific baseline covariates
that affect the outcome rate, or random center-specific deviations from the recommended
intervention, or both. We show that even in this setup, the optimal intervention can be
learned from the combined data from all stages. Even when the optimal intervention in
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the last stage does not achieve the pre-specified study goal, the optimal intervention is
estimated. We prove consistency and asymptotic normality of the new estimators utiliz-
ing a novel coupling argument. We further establish the validity of tests for an overall
intervention effect. In addition, we develop a confidence set for the optimal intervention
package and confidence bands for the target outcome probability under various observed
or hypothesized intervention packages.
2 LAGO design - theoretical development
2.1 Description of the learn-as-you-go design
The methods we develop in this paper cover an arbitrary number of stages, K. At each
stage k, a version of the intervention package is implemented in each of Jk centers. Let
njk denote the sample size (e.g. the number of births) in the j-th center at stage k. We
assume that each center is included in one stage only. In a randomized controlled trial,
centers may be randomized to either intervention or control. Alternatively, data might be
collected pre and post the implementation of the intervention package and then a center
contributes data to both the intervention and the control.
Asymptotic theory is developed for the setting where the number of patients per center
goes to infinity at the same rate in all stages, leading to reliable approximations when
the number patients in each center is relatively large. Let nk =
∑Jk
j=1 njk be the number
of participants in stage k and n =
∑K
k=1 nk be the total number of participants. Our
asymptotic inference assumes that the ratio between the number of patients in each center
and the total sample size n converges to a constant, and we write αjk = lim
n→∞
njk/n; then,∑K
k=1
∑Jk
j=1 αjk = 1. Define also n¯k = (n1, ..., nk). Proofs are given in Sections 1 and 2 of
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the supplementary materials. For ease of presentation, we first develop methodology for
a LAGO study consisting of two stages. Section 3 of the supplementary materials covers
studies with more than two stages.
The multivariate intervention package consists of p components. Let X be the support
of the intervention, that is, all possible intervention values. For example, if all p intervention
components are continuous and each is constrained to be within a given interval [Lr,Ur], r =
1, ..., p, then X = [L1,U1] × [L2,U2] × · · · × [Lp,Up]. Throughout this paper, as would
ordinarily be the case in practice, we assume that X is bounded.
For stage 1, an initial x(1) (or x
(1)
j for each center j) is chosen by the investigators,
based on their best judgment. We distinguish between the recommended intervention
and the actual intervention. In large scale public health settings, the actual intervention,
denoted by Aj , may differ from the recommended intervention, due to local constraints or
preferences. We denote zj for center-specific characteristics reflecting baseline heterogeneity
between centers with respect to the outcome of interest and we consider them fixed, i.e.,
they are not part of the intervention package. For each center, zj could be, for example,
the district of the health center or its monthly birth volume.
We assume that the probability of success for a single unit i (e.g., participant or birth)
in a center j with characteristics zj under intervention A = aj , paj(β; z) = pr(Yij = 1 |
Aj = aj,Xj = xj, zj ;β), does not depend on the recommended intervention xj, except
through the actual intervention aj, and follows a logistic regression model
logit paj (β; zj) = β0 + β
T
1 aj + β
T
2 zj , (1)
where βT = (β0,β
T
1 ,β
T
2 ) is a vector of unknown parameters, such that β1 describes the
effects of the p intervention package components. For centers in the control arm or for
pre-intervention data, if available, a = x = 0. We assume that in each stage, conditionally
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on all aj and zj , outcomes are independent within and between centers. Learning the
intervention, however, causes dependence between stages, which we consider below.
A main goal of the LAGO design is to identify the optimal intervention package. Let
p˜ be a pre-specified outcome probability goal and C(x) be a known cost function. For
example, in the BetterBirth Study, one may want to find the minimal number of on-site
coaching visits to ensure that oxytocin is administrated to the mother right after delivery
in at least 85% of births (p˜ = 0.85). If β were known, an optimal intervention for a center
with covariates zj could be the solution to the center-specific optimization problem
min
xj
C(xj) subject to pxj (β; zj) ≥ p˜ & xj ∈ X . (2)
Computational issues regarding solving (2) will be discussed in Section 2.5. We assume
that for the true parameter values, there is a unique solution to (2). For example, if the
intervention has two components with unit costs c1 and c2 and a linear cost function, we
assume that β11/c1 6= β12/c2. Alternatively, other optimization criterion can be considered.
For example, the optimal intervention could require that the intervention results in an
outcome probability p˜ when calculating a weighed average over a group of centers {j =
1, ..., J}, with sample sizes nj . That is,
min
x1,....,xJ
J∑
j=1
C(xj) subject to
1
N
J∑
j=1
njpxj (β; zj) ≥ p˜ & xj ∈ X ∀j
where N =
∑J
j=1 nj . In this paper we focus on (2).
We continue our description of the data and model. Let z¯(k) = (z
(k)
1 , ..., z
(k)
J1
) be the
observed center characteristics in each of the Jk stage k centers. We start with stage 1.
Let x
(1)
j be the recommended (multivariate) intervention package for center j in stage 1,
which in the absence of z, may be the same for all centers. We assume that the stage 1
recommended interventions x
(1)
j , j = 1, .., J1, are determined before the trial starts. The
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actual intervention in center j of stage 1 is, however, a
(1)
j = h
(1)
j (x
(1)
j ), where h
(1)
j is a
deterministic center-specific continuous function from X to X that determines how center
j implements the actual intervention based on the recommendation x
(1)
j . We do not require
that the h
(1)
j are known, but only that the a
(1)
j are observed. Let Y
(1)
ij be the binary outcome
of interest for patient i in center j of stage 1, each following model (1), and let the outcome
vector in center j of stage 1 be Y
(1)
j = (Y
(1)
1j , ..., Y
(1)
nj1j
). Let a¯(1) = (a
(1)
1 , ...,a
(1)
J1
) and
Y¯ (1) = (Y
(1)
1 , ...,Y
(1)
J1
) be the stage 1 actual interventions and outcomes, respectively.
Following the stage 1 data collection, a stage 1 analysis is conducted to determine the
recommended interventions for the new centers in stage 2, denoted by xˆ
opt,(2,n1)
j , j = 1, ..., J2.
If there are control centers, their recommended intervention and their actual intervention
are zero. The value xˆ
opt,(2,n1)
j is chosen through a function, g, that takes as input the
stage 1 data, the goal of the intervention, and the center-specific covariates and returns a
recommended intervention, which is usually the estimated optimal intervention xˆ
opt,(2,n1)
j =
g(a¯(1), Y¯ (1), z¯(1), z
(2)
j ). Then, xˆ
opt,(2,n1)
j can be obtained by solving the optimization problem
given in (2) for each center, with β replaced by an estimator βˆ(1) based on the stage 1 data
alone. The superscript, n1, in xˆ
opt,(2,n1)
j reminds us that xˆ
opt,(2,n1)
j is a random variable that
is a function of the data from the n1 participants in stage 1.
The actual intervention implemented in center j of stage 2 is A
(2,n1)
j = h
(2)
j (xˆ
opt,(2,n1)
j ),
where h
(2)
j are the analogues of h
(1)
j , but now for the stage 2 centers. Let
¯ˆxopt,(2,n1) =
(xˆ
opt,(2,n1)
1 , ..., xˆ
opt,(2,n1)
J2
) be the recommended interventions at the J2 stage 2 centers. Once
¯ˆxopt,(2,n1) are determined, stage 2 outcomes are collected under the actual interventions
A¯(2,n1) = (A
(2,n1)
1 , ...,A
(2,n1)
J2
), which may be the same as ¯ˆxopt,(2,n1). Let Y
(2,n1)
j = (Y
(2,n1)
1j , ..., Y
(2,n1)
nj2j
)
be the stage 2 outcomes in center j, each following model (1), and Y¯ (2,n1) = (Y
(2,n1)
1 , ...,Y
(2,n1)
J2
)
be all the stage 2 outcomes. Our two main assumptions are
Assumption 1 Conditionally on ¯ˆxopt,(2,n1), (A¯(2,n1), Y¯ (2,n1)) are independent of the stage
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1 data (a¯(1), Y¯ (1)).
Assumption 2 For each j = 1, ..., J2, the stage 2 recommended intervention xˆ
opt,(2,n1)
j
converges in probability to a center-specific limit x
(2)
j .
Assumption 1 assumes that learning takes place only through the determination of the
recommended intervention. It ensures that the dependence between the stage 1 data
and stage 2 outcomes is solely due to the dependence of the xˆ
opt,(2,n1)
j on the stage 1
data. It specifically means that, given ¯ˆxopt,(2,n1), the actual intervention in a stage 2
center is conditionally independent of Y¯ (1). Under Assumption 1, and the aforemen-
tioned assumption that conditionally on the actual interventions, the outcomes do not
depend on the recommended interventions, we can conclude that in stage 2, pr(Y¯ (2,n1) |
A¯(2,n1), ¯ˆxopt,(2,n1), z¯(2), Y¯ (1)) = pr(Y¯ (2,n1) | A¯(2,n1), z¯(2)), so the logistic regression model
(1) holds for the stage 2 data. Assumption 2 implies that in the presence of more and
more stage 1 data under a
(1)
j , j = 1, ..., J1, each of the estimated optimal intervention
packages xˆ
opt,(2,n1)
j , j = 1, ...J2, converges in probability to a fixed value x
(2)
j . For exam-
ple, Assumption 2 will hold if ¯ˆxopt,(2,n1) are continuous functions of the stage 1 maximum
likelihood estimator, βˆ1, as is the case if xˆ
opt,(2,n1)
j solves (2) and β11/c1 6= β12/c2. Under
Assumption 2 and continuity of the hj’s, the Continuous Mapping Theorem implies that
A
(2,n1)
j = h
(2)
j (xˆ
opt,(2,n1)
j ) converges in probability to a
(2)
j = h
(2)
j (x
(2)
j ).
In fact, the results we prove in this paper regarding the estimators obtained at the end
of the study hold not only for g(a¯(1), Y¯ (1), z¯(1), z
(2)
j ) = xˆ
opt,(2,n1)
j , but under any choice of
function g for the recommended intervention, as long as Assumption 2 holds. Further details
about g and proofs of this claim are given in Section 2 of the supplementary materials.
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2.2 βˆ and its asymptotic properties
We estimate β after the K stages are concluded. As in previous sections, for ease of
development, we consider here K = 2. Section 3 of the supplementary materials covers the
case of K > 2.
We propose to estimate β by solving the estimating equations
0 = U(β) =
1
n


J1∑
j=1
nj1∑
i=1


1
a
(1)
j
z
(1)
j


(
Y
(1)
ij − pa(1)j
(β; z
(1)
j )
)
+
J2∑
j=1
nj2∑
i=1


1
A
(2,n1)
j
z
(2)
j


(
Y
(2,n1)
ij − pA(2,n1)j
(β; z
(2)
j )
)


.
(3)
In Section 2.1 of the supplementary materials, we show that the estimator βˆ that solves
(3) is also a maximum partial likelihood estimator, although it is not needed for the proofs
below. These estimating equations (3) also arise if the interventions were determined a
priori, so βˆ can be estimated using standard software.
Asymptotic theory for βˆ is complicated, however, by the fact that Y¯ (1) and (A¯(2,n1), Y¯ (2,n1))
are not independent. Thus, the score function, U(β), is not a sum of independent random
variables.
Let B be the parameter space for β. A conditional expectations argument (Equation
(A.9) in the supplementary materials) shows that the score function has mean zero when
evaluated at the true value, denoted by β⋆. Furthermore, we show in the supplementary
materials (Equation (A.10)) that the two terms in (3), although dependent, are uncorre-
lated. These two properties are useful for proving that βˆ is consistent:
Theorem 1 (Consistency) Assume B is compact. Under Assumptions 1 and 2, βˆ
P
−→ β⋆.
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The proof is given in Section 2.2 of the supplementary materials.
Asymptotic normality also poses a challenge due to the dependence between the two
summands in U(β). It can be shown that ∂U(β)/∂β converges in probability to −I(β),
for all β ∈ B, with I(β) given in Section 2.3 of the supplementary materials. The following
theorem establishes asymptotic normality of βˆ:
Theorem 2 (Asymptotic normality) Under Assumptions 1 and 2,
n1/2(βˆ − β⋆)
D
−→ N
(
0, I−1(β⋆)
)
. (4)
The full proof of Theorem 2 is given in Section 2.3 of the supplementary materials. Here
we outline the main parts of the proof, which rests upon a novel coupling argument. First,
by the mean value theorem and further arguments, it can be shown that the asymptotic
distribution of n1/2(βˆ − β⋆) is the same as the asymptotic distribution of
[I(β⋆)]−1n−1/2


J1∑
j=1
nj1∑
i=1


1
a
(1)
j
z
(1)
j


(
Y
(1)
ij − pa(1)j
(β⋆; z
(1)
j )
)
+
J2∑
j=1
nj2∑
i=1


1
A
(2,n1)
j
z
(2)
j


(
Y
(2,n1)
ij − pA(2,n1)j
(β⋆; z
(2)
j )
)

 .
(5)
We next show that the asymptotic distribution of the part of (5) that does not involve
I(β⋆) is multivariate normal. The following coupling argument deals with the fact that the
two summands in (5) are not independent. For each j = 1, ..., J2, let Y
(2)
ij , i = 1, ..., nj2,
be independent Bernoulli random variables, independent of all stage 1 data, with success
probability p
a
(2)
j
(β⋆; z
(2)
j ), where, as defined before, a
(2)
j = h
(2)
j (x
(2)
j ). We construct variables
Y˜
(2,n1)
ij which, given the stage 1 data and the A
(2,n1)
j , have the same distribution as the
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original Y
(2,n1)
ij , but coupled (see e.g. Lindvall (2002)) with the Y
(2)
ij in the following way.
Let Wij be independent uniform (0, 1) random variables, independent of all other variables
introduced so far. For the case p
a
(2)
j
(β⋆; z
(2)
j ) > pA(2,n1)j
(β⋆; z
(2)
j ), let
Y˜
(2,n1)
ij =


0 if Y
(2)
ij = 0
0 if Y
(2)
ij = 1 and Wij <
p
a
(2)
j
(β⋆;z
(2)
j )−p
A
(2,n1)
j
(β⋆;z
(2)
j )
p
a
(2)
j
(β⋆;z
(2)
j )
1 if Y
(2)
ij = 1 and Wij ≥
p
a
(2)
j
(β⋆;z
(2)
j )−p
A
(2,n1)
j
(β⋆;z
(2)
j )
p
a
(2)
j
(β⋆;z
(2)
j )
.
A similar expression is given in the supplementary materials for the case p
a
(2)
j
(β⋆; z
(2)
j ) ≤
p
A
(2,n1)
j
(β⋆; z
(2)
j ). The key property of the coupling argument is that given A
(2,n1)
j and the
stage 1 data, the distribution of the coupled Y˜
(2,n1)
ij is identical to the distribution of the
original Y
(2,n1)
ij . Therefore, when we replace Y
(2,n1)
ij with Y˜
(2,n1)
ij in (5), the distribution of
(5) is unaffected. In the supplementary materials, we use the coupled outcomes to show
that the part of (5) that does not involve I(β⋆) has the same asymptotic distribution as
n−1/2
{
J1∑
j=1
nj1∑
i=1


1
a
(1)
j
z
(1)
j


(
Y
(1)
ij − pa(1)
j
(β⋆; z
(2)
j )
)
+
J2∑
j=1
nj2∑
i=1


1
a
(2)
j
z
(2)
j


(
Y
(2)
ij − pa(2)
j
(β⋆; z
(2)
j )
)}
.
(6)
The outcomes Y¯ (1) and Y¯ (2) = (Y¯
(2)
1 , ..., Y¯
(2)
J2
) are independent, because the Y
(2)
ij are the
outcomes under the constant intervention a
(2)
j . Therefore, by standard logistic regression
theory, the expression in (6) converges in distribution to a normal random variable with
mean zero and variance I(β⋆). Combining the asymptotic normality of (6) with (5) implies
that Theorem 2 holds.
The asymptotic variance can be consistently estimated from the data by replacing a
(2)
j ,
β⋆, αj1 and αj2 with A
(2,n1)
j , βˆ, nj1/n and nj2/n, respectively, in I(β
⋆). The asymptotic
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variance and its approximation are the same as if the interventions were fixed in advance
and Y¯ (1) and Y¯ (2,n1) were independent.
2.3 Hypothesis testing
A major goal of a LAGO study is to test the null hypothesis of no overall intervention
effect. One way to test this is to carry out a test for the subvector of β characterizing the
effect of the intervention. That is, to test H0 : β1 = 0 in model (1) using the asymptotic
normality result of Section 2.2. Because of this asymptotic normality result, the Wald or
likelihood ratio tests for H0 : β1 = β
0
1 are asymptotically valid for any constant β
0
1.
Alternatively, in a controlled LAGO design, let Q be a group indicator that equals
one for the intervention group and zero for the control, and let p0 and p1 be the success
probabilities under Q = 0 and Q = 1, respectively. Then, an alternative test for an overall
intervention effect, H0 : β1 = 0, can be carried out by testing H0 : p0 = p1. The latter test is
valid despite the adaption of the intervention package. By Assumption 1, the dependence
between the stage 2 and stage 1 data is solely due to the stage 1 data determining the
stage 2 recommended intervention, which, in turn, affects the actual stage 2 intervention,
and thus the stage 2 outcomes. However, under the null, there is no effect of the actual
intervention on the stage 2 outcomes. Therefore, under the null, regardless of the way
the intervention was adapted, the stage 1 and stage 2 outcomes are independent. Thus,
a standard test for equal probabilities in the control and the intervention arms is valid.
While not needed due to our asymptotic results, the same arguments could have been used
for the standard tests of H0 : β1 = 0.
In a controlled LAGO design, an alternative, possibly more powerful, test for the overall
effect of the intervention in the presence of center characteristics is to consider H0 : γ = 0
in the model logit p˜Q(β, γ; z) = β0 + β
T
2 z + γQ. As before, in light of the between-stages
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independence under the null, β1 = 0 in model (1) implies γ = 0.
2.4 Confidence sets and confidence bands
After the conclusion of the study, the optimal intervention is estimated as the solution to
(2) with β replaced by βˆ. To obtain an asymptotic 95% confidence set for the optimal
intervention xopt, we first obtain a confidence interval for px(β
⋆; z˜), for a given z = z˜ and
for each x ∈ X . To do this, we calculate a 95% confidence interval for logit(px(β
⋆; z˜)), i.e.,
for (1 xT z˜T )β⋆:
CIx =
[
(1 xT z˜T )βˆ − 1.96σ(βˆ;x, z˜), (1 xT z˜T )βˆ + 1.96σ(βˆ;x, z˜)
]
,
where σ2(βˆ;x, z˜) = (1 xT z˜T )n−1Iˆ−1(βˆ)(1 xT z˜T )T is the estimated variance of (1 xT z˜T )βˆ,
and n−1Iˆ−1(βˆ) is the estimated variance of βˆ. The 95% confidence interval for px(β
⋆; z˜)
is CIpx = expit(CIx). Then, we obtain the confidence set for the optimal intervention as
CS(xopt) = {x : CIpx ∋ p˜}. That is, CS(x
opt) includes intervention packages for which p˜
is inside the confidence interval for the success probability under those interventions.
We now show that the confidence set CS(xopt) contains xopt with the specified prob-
ability of 0.95. Recall that under the assumption that p˜ can be achieved, pxopt(β
⋆; z˜) =
expit[(1 xopt
T
z˜T )β⋆] = p˜. Therefore,
pr(CS(xopt) ∋ xopt) = Pr(CIp
xopt
∋ p˜) = Pr(CIp
xopt
∋ pxopt(β
⋆; z˜)) = 0.95.
Implementing this procedure is simple and its calculation is fast. Because calculating
CS(xopt) does not depend upon estimating xopt, it does not involve the optimization algo-
rithm.
At the end of the study, researchers might be interested in a variety of potential in-
tervention packages in X that were not necessarily identified as of interest a priori. We
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propose a method to develop confidence bands for the outcome probabilities px(β; z˜) for
a range of x ∈ X of interest, simultaneously. These confidence bands allow researchers to
study the entire intervention space when comparing potential choices of the intervention
package. We propose a procedure that is based on the asymptotic normality of βˆ and
on Scheffe´’s method (Scheffe´, 1959). First, for all x ∈ X , construct CBx to obtain 95%
confidence bands for {(1 xT z˜T )β⋆ : x ∈ X},
CBx =
[
(1 xT z˜T )βˆ − χ20.95,p+q+1σ(βˆ;x, z˜), (1 x
T z˜T )βˆ + χ20.95,p+q+1σ(βˆ;x, z˜),
]
,
with σ(βˆ;x, z˜) defined as before and χ20.95,p+q+1 the 95% quantile of a χ
2
p+q+1 distribu-
tion. As before, we transform CBx into confidence bands for px(β; z˜) by setting CBpx =
expit(CBx). These confidence bands guarantee asymptotic simultaneous 95% coverage
for all possible intervention package compositions; the proof is given in Section 4 of the
supplementary materials.
2.5 Computation of the optimal intervention
The algorithm used to solve (2) after stage k, using βˆ(k), depends on the form of C(x).
Under a linear cost function with unit costs cr for the r–th component of the intervention,
the solution is achieved by 1. setting all components to their minimal value Lr, 2. ordering
the components by their estimated cost-efficiency βˆ1r/cr, and 3. increasing the most cost-
efficient component until either p˜ is achieved or until this component reaches its maximal
value, and then moving to the next most cost-efficient component among the remaining
components. For non-linear cost functions, standard non-linear optimization algorithms
can be used.
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3 Simulations
We conducted simulation studies to investigate the finite sample properties of our methods.
We simulated 1000 data sets per simulation scenario. We considered a two-stage controlled
LAGO design with equal number of centers per stage J , with half the centers in the
intervention arm and half in the control arm. The total sample size available at the end
of the study is J(n1j + n2j). We considered the values J = 6, 10, 20, n1j = 50, 100, 200,
and n2j = 100, 200, 500, 1000. The intervention had two components, x = (x1, x2), with
unit costs c1 = 1 and c2 = 8. The minimum and maximum values of X1 and X2 were
[L1,U1] = [0, 2] and [L2,U2] = [0, 5]. We considered the following values for exp(β
⋆
1) =
(exp(β⋆11), exp(β
⋆
12)): (1, 1) (the null), (1, 1.2), (1, 1.5), (1.2, 1.5), and (1.2, 2). A single
center covariate z was normally distributed with mean 0 and variance 1 and its coefficient
was taken to be β⋆2 = log(0.75). For simplicity, we did not include an intercept in model
(1), although each center had its own baseline success probability due to z. For z = 0, the
probability of success in the control arm was 0.5. The stage 2 recommended intervention
was based on solving the optimization problem (2) using the stage 1 estimates of β. Section
5.1 of the supplementary materials provides the details on what was done when no solution
existed for which p˜ was reached.
Selected results are presented in Tables 1 and 2. Table 1 presents results on the per-
formance of βˆ, and shows that for J > 6, the finite sample bias was minimal, the mean
estimated standard error was very close to the empirical standard deviation, and the em-
pirical coverage rate of the confidence intervals for the effects of the individual package
components was very close to 95%. Moreover, Section 5.2 of the supplementary shows that
the type I error rate of the tests discussed in Section 2.3 was close to 0.05.
Table 2 presents results for the estimated optimal intervention and success probabilities,
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Table 1: Simulation study: results for individual package component effects. Unit costs
were c1 = 1 and c2 = 8.
exp(β⋆) n1j n2j J βˆ11 βˆ12
%RelBias SE/EMP.SD CP95 %RelBias SE/EMP.SD CP95
(×100) (×100)
(1.2, 1.5) 50 100 6 -1.1 92.0 95.2 -2.1 83.3 94.2
10 -3.0 100.1 95.6 -0.8 93.4 94.9
20 0.1 103.5 95.5 -0.6 104.9 96.1
200 6 -3.0 88.4 94.9 -3.1 83.5 95.2
10 -6.6 92.9 94.5 -0.9 93.5 94.9
20 0.2 102.5 95.6 -0.6 97.7 95.3
100 100 6 -0.8 89.5 95.1 -1.6 86.7 95.2
10 3.5 102.2 95.7 -1.3 102.2 95.0
20 1.5 100.7 95.3 -0.4 101.1 95.2
200 6 -2.2 90.4 94.6 -1.4 89.7 96.0
10 -0.8 102.7 96.7 -0.7 95.9 95.5
20 -0.3 97.4 94.7 -0.4 96.7 94.1
(1.2, 2) 50 100 6 -11.4 89.0 94.8 -0.4 82.2 96.1
10 -7.3 103.7 95.7 0.4 104.4 96.5
20 -3.1 99.0 94.7 -0.1 100.8 95.0
200 6 -15.8 92.6 95.0 1.4 89.7 94.9
10 -8.1 93.3 95.7 0.3 99.6 95.5
20 -1.8 100.1 95.3 -0.5 102.5 96.6
100 100 6 -6.0 96.2 96.3 0.0 94.0 95.2
10 -2.7 98.2 95.1 -0.2 104.7 95.4
20 -2.7 100.7 95.2 0.2 102.2 95.2
200 6 -8.9 95.4 95.4 0.3 83.8 96.5
10 -5.0 95.6 94.6 0.0 97.3 95.3
20 -3.2 98.9 94.4 0.1 104.7 95.5
%RelBias, percent relative bias 100(βˆ − β⋆)/β⋆; SE, mean estimated standard error; EMP.SD, empirical
standard deviation; CP95, empirical coverage rate of 95% confidence intervals.
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for J = 20 and calculated for a typical center with z = 0; results for J = 6, 10 are presented
in Section 5.2 of the supplementary materials. The finite sample bias and the root mean
squared errors of the final xˆopt were generally small and decreased as the number of centers
per stage and the sample size increased. The nominal coverage rate of the confidence set
for xopt was approximately 95%, with the set typically including between 3 to 14 percent
of X , as a measure of precision in the scenarios studied. We also compared the cost of the
estimated optimal intervention to the cost of the true optimal intervention and found it to be
almost the same for the scenarios presented in Table 2; see Section 5.2 in the supplementary
materials. Table 2 also shows that the empirical coverage rate of the confidence bands for
px(β
⋆; z = 0) was very close to 95%.
4 Illustrative example
The BetterBirth Study consisted of three stages. The first two stages were pilot stages
used to develop the intervention package. Stage 3 was a randomized controlled trial. The
development of the recommended intervention package was conducted qualitatively, as
described in Hirschhorn et al. (2015), and the intervention package was adjusted after each
pilot stage. The results of the randomized controlled trial were presented and discussed
in Semrau et al. (2017). The number of centers with data on oxytocin administration in
the first, second, and third stages was 2, 4 and 30, respectively. In the first two stages,
data in each center were collected before and after the intervention was implemented. In
stage 3, there were 15 centers in the control arm and 15 centers in the intervention arm.
In 5 intervention arm centers, outcome data were also collected before the intervention was
implemented.
Here, we focus on the binary outcome of oxytocin administration immediately after
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Table 2: Simulation study: results for estimated optimal intervention package and coverage
of 95% confidence bands for success probabilities. Unit costs were c1 = 1 and c2 = 8.
Results presented for J = 20 centers per stage.
exp(β⋆) xopt n1j n2j Bias(x
opt
1
) Bias(xopt
2
) RMSE(xopt) SetCP95 SetPerc% BandsCP95
(×100) (×100) (×100)
(1, 2) (0, 3.2) 50 100 36.4 -5.0 87.3 94.8 7.6 96.9
500 18.6 -2.4 62.0 95.2 4.1 96.8
100 100 22.6 -2.8 69.0 94.5 6.1 96.7
500 9.8 -1.3 45.3 94.5 3.7 97.5
(1.2, 1.5) (2, 4.5) 50 100 -8.4 2.4 48.9 94.4 13.3 96.8
500 -1.9 0.9 25.0 94.9 7.7 95.9
100 100 -4.4 1.3 38.4 94.6 12.3 95.5
500 -0.6 2.2 18.4 94.8 7.1 95.5
(1.2, 2) (2, 2.6) 50 100 -31.2 4.0 81.6 94.0 14.2 95.0
500 -15.2 3.3 57.1 94.9 8.0 94.8
100 100 -21.8 2.7 68.3 95.1 12.4 95.4
500 -9.0 2.6 44.1 94.3 7.5 95.0
RMSE, root of mean squared errors {mean(||xˆopt − xopt||2)}1/2, mean taken over simulation iterations;
SetCP95, empirical coverage percentage of confidence set for optimal intervention; SetPerc%, mean
percent of X covered by the confidence set; BandsCP95, empirical coverage rate of 95% confidence bands
for {px(β; z = 0) : x ∈ X}.
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delivery, as recommended by the WHO (WHO, 2012) to prevent postpartum hemorrhage,
a major cause of maternal mortality. The intervention package components were the du-
ration of the on-site intervention launch (in days), the number of coaching visits after the
intervention was launched, leadership engagement (non-standardized initial engagement,
standardized initial engagement, and standardized initial engagement with follow-up visits)
and data feedback (none; ongoing, paper-based; ongoing, app-based). The four components
were adapted in a way that resulted in near multicollinearity. Therefore, for illustration
purposes, we considered the first two components only, launch duration and number of
coaching visits. The launch duration was 3 days in stage 1 and 2 days in stages 2 and 3.
Compared to stage 1, the intensity of coaching visits was increased in stage 2, and further
increased in stage 3. For illustrative purposes, we truncated the data at 40 coaching visits
or less. The baseline center characteristic we included was the approximate monthly birth
volume, given that large facilities might be likely to follow WHO recommendations about
oxytocin administration more closely, regardless of the intervention package implemented.
Other available center characteristics, e.g. number of staff nurses, were highly correlated
with the monthly birth volume.
Table 3 provides the estimated effects of the intervention package components after
each of the stages, using all available data at that point. The sample size in stage 1 was
relatively small, explaining the wide confidence intervals for the odds ratios. The final
results imply that both package components had an effect. Tests for the overall effect of
the package yielded a highly significant p-value, regardless of the test we used.
After consulting with the study investigators, we assigned unit costs of $800 per launch
day and $170 per coaching visit. In practice, implementation costs may also depend on
center size and, if so, C(x) could be replaced with Cz(x).
The estimation of the optimal intervention package with linear cost C(x) = c1x1+ c2x2
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Table 3: Package component effect estimates and confidence intervals, calculated after each
stage.
Stage 1 Stages 1-2 Stages 1-3
n1 = 73 (n1 + n2 = 1780) (n1 + n2 + n3 = n = 6124)
OR (CI-OR) OR (CI-OR) OR (CI-OR)
Intercept 1.07 (0.00, 280.80) 0.10 (0.07,0.15) 0.10 (0.09,0.11)
Coaching Visits 7.95 (1.77,73.95) 1.11 (0.96,1.28) 1.08 (1.04,1.12)
(per 3 visits)
Launch Duration 1.41 (0.76,2.64) 2.65 (1.95,3.77) 2.79 (2.41,3.23)
(days)
Birth Volume 0.37 (0.00,32.33) 2.11 (1.93,2.33) 1.94 (1.84,2.06)
(monthly, per 100)
xˆopt,(2,n1) = (1, 5) xˆopt,(3,(n1,n2)) = (3, 1) xˆopt = (3, 1)
OR, estimated odds ratio exp(βˆ); CI-OR, 95% Confidence interval for the odds ratio. In the estimated
optimal interventions, the first component is the launch duration (in days) and the second component is
the number of coaching visits .
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was conducted as in the simulation study. Assuming that at least 1 launch day and 1
coaching visit are needed, and that a launch duration of more than 5 days or having
more than 40 coaching visits is impractical, we estimated the optimal intervention for a
center with average birth volume (z = 175) to be a launch duration of 2.78 days and 1
coaching visit. We also carried out optimization over all possible combinations of discrete
values within X , which are 1, ..., 40 coaching visits and 1, 1.5, 2, 2.5, ..., 5 for duration of
intervention launch and obtained the optimal intervention as launch duration of three days
with one coaching visit, xˆopt = (3, 1). The total cost of the estimated optimal intervention
package, xˆopt, was $2570.
We calculated a 95% confidence set for the optimal intervention CS(xopt) over the
grid of X , taking all possible numbers of coaching visits, 1, ..., 40, and 1, 1.5., 2, 2.5, ..., 5
for intervention launch duration. Out of 360 potential intervention packages, 38 (10.5%)
were included in the 95% confidence set. The set included the following combinations:
1.5 days launch duration and 40 coaching visits; 2 days launch durations and 27 or more
coaching visits; 2.5 days launch duration and less than 20 coaching visits; and 3 days
launch duration and less than 5 coaching visits. The first, second and third quartiles of
the cost distribution within CS(xopt) were Q1=$2462, Q2=$4035, and Q3=$6797. We also
calculated 95% simultaneous confidence bands for the probability of success under all 360
intervention compositions; plots are shown in Section 6 of the supplementary materials. For
the estimated optimal intervention xˆopt = (1, 3), the obtained interval within the bands for
the probability of oxytocin administration was (0.79, 0.93). The mean difference between
the top and bottom of the confidence band over all 360 intervention compositions was 0.07.
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5 Discussion
We developed the LAGO design for multiple component intervention studies with a binary
outcome, where the intervention package composition is systematically adapted as part of
the design. The goals of studies using the LAGO design are to find the optimal intervention
package, to test its effect on the outcome of interest, and to estimate its effect as well as
the effects of the individual components
The methodology in this paper was developed for scenarios with a stagewise analysis
that does not include formal interim hypothesis testing. However, the LAGO design allows
for futility stops, since stopping the trial for futility between stages preserves the type I
error. The type I error can only decrease from the nominal level when futility stops are
included because when stopping for futility, the null is not rejected (Snapinn et al., 2006).
For clear presentation of the design, methods, and theory, we focused on a general yet
practical design. Our work opens the way for further research. For example, it would
be interesting to develop methods for studies with further dependence because centers
contribute data to more than one stage. The results in this paper could also be extended
to continuous, count, or survival outcome data. Finally, many design problems arise, in
terms of identifying the optimal K, Jk and njk for given settings.
Many large effectiveness and implementation trials fail because current design method-
ology does not permit adaptation in the face of implementation failure as in, for example,
the BetterBirth (Semrau et al., 2017) and the TasP (Iwuji et al., 2017) studies. The LAGO
design rigorously formalizes practices in public health research that are presently conducted
in an ad hoc manner, with unknown consequences for the validity of the subsequent stan-
dard analysis (Escoffery et al., 2018). We expect widespread use of the LAGO design as a
result, with potential gain for many randomized clinical trials.
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